Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020

11/09/2020 | 08:01am EST

- Presentations Demonstrate Ability of Seagen Antibody-Drug Conjugates to Elicit Immunogenic Cell Death Effect Across Multiple Tumor Types -

- Data Features Seagen’s Sugar-Engineered Antibodies as part of an Emerging, Innovative Immuno-Oncology Pipeline -

Seagen Inc. (Nasdaq:SGEN) today announced the presentation of immuno-oncology data from its broad pipeline of therapies at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting 2020, taking place virtually November 9-14, 2020. Six abstracts will highlight the company’s continued progress in advancing innovative research for marketed and late-stage antibody-drug conjugates (ADCs) and innovative empowered antibody pipeline utilizing its proprietary sugar-engineering antibody (SEA) technology.

Data presented at SITC will demonstrate how Seagen’s monomethyl auristatin E (MMAE)-based ADCs induce immunogenic cell death (ICD) by activating the innate immune cells and changing the tumor microenvironment to a more inflammatory state thereby enhancing the efficacy of other cancer immunotherapies. These findings will be presented for tisotumab vedotin, ladiratuzumab vedotin and across vedotin-based ADCs (Abstracts #617, #618 and #323).

“Our vedotin-based ADC research at SITC illustrates the impact of immunogenic cell death on the tumor microenvironment,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Importantly, these data support the mechanistic rationale for combining vedotin-based ADCs with immuno-oncology therapies in the clinic.”

Data will also be presented utilizing Seagen’s proprietary SEA technology, which produces nonfucosylated antibodies that uniquely enhance activity targeting key immune modulating receptors. Preclinical data will be presented from SEA-TGT (Abstract #250), a novel investigational nonfucosylated human IgG1 TIGIT antibody. SEA-TGT is in an ongoing phase 1 clinical trial for patients with solid tumors and lymphoma (NCT04254107). In addition, preclinical data will be presented for SEA-CD40 (Abstract #438), a novel investigational, nonfucosylated human IgG1 antibody targeted to CD40, an immune stimulatory receptor found on antigen-presenting cells. SEA-CD40 is in a phase 1 trial for pancreatic cancer in combination with chemotherapy and a PD-1 inhibitor (NCT02376699).

“We believe our immuno-oncology candidates have a best-in-class potential, creating a strong foundation for our immunotherapy pipeline,” said Scott Peterson, Ph.D., Senior Vice President of Research at Seagen. “Data presented at SITC demonstrate that our sugar-engineered antibodies are differentiated and have the potential to improve efficacy and address unmet needs in cancer.”

Data regarding ADCETRIS® (brentuximab vedotin) will be presented demonstrating its ability to selectively target and kill CD30-positive T regulatory cells (Tregs) that contribute to resistance to cancer immunotherapies (Abstract #696). These data support that ADCETRIS may have an immunomodulatory effect through selective depletion of highly active Tregs.

The abstracts published in advance of the SITC Annual Meeting can be found here. All data presentations will be available on-demand starting on November 11, 2020.

Details of Seagen Presentations at SITC Annual Meeting 2020:

Abstract Title

Abstract No.

Presentation

Type / Date

Presenter

Brentuximab vedotin, a CD30 targeting antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo

#696

E-Poster /

November 11-14

B. Grogan

Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

#617

E-Poster /

November 11-14

E. Gray

Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

#323

E-Poster /

November 11-14

L. Pusztai

Synergy between SEA-CD40 and chemotherapeutics drives curative anti-tumor activity in pre-clinical models

#438

E-Poster /

November 11-14

W. Zeng

SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon FcγR engagement

#250

E-Poster /

November 11-14

A. Smith

Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

#618

E-Poster /

November 11-14

K. Klussman

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the ability of vedotin-based ADCs to enhance the efficacy of immune-oncology therapies, the potential of the Company’s SEA-TGT and SEA-CD40 product candidates and the potential of the Company’s immunotherapy pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


© Business Wire 2020
All news about SEAGEN INC.
01/15SEAGEN : BofA Securities Upgrades Seagen to Buy from Neutral, Sets $215 Price Ta..
MT
01/07SEAGEN : to Host Conference Call and Webcast Discussion of Fourth Quarter and Fu..
BU
2020SEAGEN : Registers Mixed-Securities Shelf Offering
MT
2020SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020SEAGEN : to Present at the J.P. Morgan Healthcare Conference
BU
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA for the Treatment of Patient..
AQ
2020Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
AQ
2020SEAGEN : Says European Regulatory Committee Recommends Approval of Tukysa in Bre..
MT
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatme..
BU
2020Boehringer gets into 'guided-missile drugs' with $1.5 billion deal for NBE
RE
More news
Financials (USD)
Sales 2020 2 163 M - -
Net income 2020 598 M - -
Net cash 2020 1 943 M - -
P/E ratio 2020 55,2x
Yield 2020 -
Capitalization 33 059 M 33 059 M -
EV / Sales 2020 14,4x
EV / Sales 2021 16,9x
Nbr of Employees 1 605
Free-Float 99,4%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 198,71 $
Last Close Price 182,75 $
Spread / Highest target 39,0%
Spread / Average Target 8,73%
Spread / Lowest Target -24,5%
EPS Revisions
Managers and Directors
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.4.35%33 059
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266